CSL Annual Report 2023

Directors’ Report 9. Environmental regulation and compliance To meet industry and regulatory standards at our facilities, CSL uses an Environmental, Health and Safety (EHS) Management System. This system covers compliance with government regulations and commitments for continuous improvement of health and safety in the workplace, as well as minimising the negative effects of operations on the environment. In 2022/23, CSL improved global alignment across several key EHS programs. This included updating the Global EHS audit and governance program and the development of standardised global processes to identify and control activities, where the absence or failure to use a control could expose employees to serious injury or fatality. The focus on the identification and standardised control of EHS risk across the CSL network will continue in 2023/24. CSL continues to mature our overall environmental sustainability program, imbedding environmental considerations into our work practices. Key environmental principles are driven by processes like our EHS by Design program (and the operational identification of environmental aspects and impacts), in alignment with ISO 14001 principles, to further reduce CSL’s potential impact on the environment and our local communities. Our Australian subsidiaries continue to be classified as an established licensee in respect of CSL’s self-insurance license as granted by the Safety, Rehabilitation and Compensation Commission with an eight-year license extension granted in 2023. The following notices were provided to CSL by local government agencies in 2022/23: • In 2022, CSL Seqirus, Holly Springs (United States) received a Notice of Violation (lowest level of violation with no monetary impact) from the state Department of Environmental Quality (DEQ). The notice was associated with some minor labelling and administrative document updates. • In 2022, CSL Plasma (United States) received an Occupational Safety and Health Administration (OSHA) Citation: Other than serious, with non-monetary violation for non-contiguous blood borne pathogen procedure. • In 2023, CSL Plasma (United States) received an OSHA Citation: Other than serious, with a US$600 fine for failing to report an employee hospitalisation within the required time frame. • In 2023 CSL’s facility in Pasadena (United States) received a violation with no monetary impact from the local fire department, for a flammable cabinet in one of the research labs that did not have an automatic closure device. • In 2023, CSL’s facility in Wuhan (China) was issued a violation by the environmental protection authority for failing to meet discharge limits of chemical oxygen demand (COD) as outlined in the site’s discharge permit. The penalty issued was US$16,548 (RMB120,000). CSL has met its reporting obligations under the Australian Government’s National Greenhouse and Energy Reporting Act 2007 and Victorian Government’s Industrial Waste Management Policy (National Pollutant Inventory). Additional EHS performance details, including workplace safety, can be found in CSL’s People on page 40 and Environment on page 46. 10. Directors’ shareholdings and interests The interests of the directors in the shares, options and performance rights of CSL are set out in the Remuneration Report – Tables 11 and 12 for executive key management personnel (KMP) and Tables 16 and 17 for non-executive directors. The Group’s Securities Dealing Policy prohibits KMP from entering into transactions which limit exposure to risk in relation to securities granted under CSL’s equity incentive schemes. From time to time the Company Secretary makes inquiries of KMP as to their compliance with this policy. 11. Performance rights and options As at 30 June 2023, the number of unissued ordinary shares in CSL under options and under performance rights are set out in Note 6 (People Costs) and Note 19 (Detailed Information – Shareholder Returns) of the Financial Statements. Holders of options or performance rights do not have any right, by virtue of the options or performance rights, to participate in any share issue by CSL or any other body corporate or in any interest issued by any registered managed investment scheme. The number of options and performance rights exercised during the financial year and the exercise price paid to acquire fully paid ordinary shares in CSL is set out in Note 6 (People Costs) of the Financial Statements. Since the end of the financial year, no shares were issued under CSL’s Performance Rights Plan. Since the end of the financial year, 2,124 Restricted Share Units have been forfeited due to participant cessation of employment. There has been no change to the information contained in Note 18 (Detailed Information – People Costs) to the Financial Statements or Note 19 (Detailed Information – Shareholder Returns). 12. Indemnification of directors and officers During the financial year, the insurance and indemnity arrangements discussed below were in place concerning directors and officers of the consolidated entity. CSL has entered into a Director’s Deed with each director regarding access to Board papers, indemnity and insurance. Each deed provides: 1. an ongoing indemnity to the relevant director against liability incurred by that director as an officer of CSL or a related body corporate. The indemnity is given to the extent permitted by law and to the extent and for the amount that the relevant director is not otherwise entitled to be, and is not actually, indemnified by another person or out of the assets of a corporation, where the liability is incurred in or arising out of the conduct of the business of that corporation or in the discharge of the duties of the director in relation to that corporation; CSL Limited Annual Report 2022/23 78

RkJQdWJsaXNoZXIy MjE2NDg3